<DOC>
	<DOCNO>NCT00772668</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy , cyclophosphamide prednisone , work different way stop growth cancer cell , either kill cell stop dividing . Bortezomib may stop growth cancer cell block enzymes need cell growth block blood flow tumor . Giving rituximab together cyclophosphamide , bortezomib , prednisone may kill cancer cell . PURPOSE : This clinical trial study well give rituximab together cyclophosphamide , bortezomib , prednisone work first-line therapy treat patient stage III stage IV follicular lymphoma marginal zone lymphoma .</brief_summary>
	<brief_title>Rituximab , Cyclophosphamide , Bortezomib , Prednisone Treating Patients With Stage III Stage IV Follicular Lymphoma Marginal Zone Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine overall response rate , term complete response ( CR ) , unconfirmed CR , partial response , patient follicular lymphoma marginal zone lymphoma treat rituximab , cyclophosphamide , bortezomib , prednisone ( R-CVelP ) first line treatment . Secondary - To determine progression-free survival patient treat regimen . - To determine overall survival patient treat regimen . - To determine safety tolerance R-CVelP patient . OUTLINE : - Induction therapy : Patients receive rituximab IV cyclophosphamide IV 30 minute day 1 , bortezomib IV day 1 8 , oral prednisone daily day 1-5 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . Patients proceed maintenance therapy . - Maintenance therapy : Patients receive rituximab IV day 1 , 8 , 15 , 22 . Treatment repeat every 6 month 4 course absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 4 month 1 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm grade 1 2 follicular lymphoma ( FL ) marginal zone lymphoma ( MZL ) Stage III IV disease Measurable evaluable disease Previously untreated disease PATIENT CHARACTERISTICS : ECOG performance status 13 ANC &gt; 1,000/mm³ Platelet count &gt; 100,000/mm³ ( unless due lymphoma ) Bilirubin &lt; 2.0 mg/dL Creatinine &lt; 2 mg/dL ( unless due lymphoma ) AST , ALT , alkaline phosphatase &lt; 3 time upper limit normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No myocardial infarction within past 6 month No NYHA class IIIIV heart failure No uncontrolled angina No severe uncontrolled ventricular arrhythmia No ECG evidence acute ischemia active conductive system abnormalities No hypersensitivity boron mannitol No serious medical psychiatric illness likely interfere participation clinical study No history HIV infection No concurrent previous malignancy poor prognosis ( &lt; 90 % probability survival 5 year ) actively treat second malignancy No peripheral neuropathy ≥ grade 2 within past 14 day PRIOR CONCURRENT THERAPY : No prior therapy disease include chemotherapy , singleagent rituximab , radiotherapy No concurrent anticancer therapy include chemotherapy , radiation , hormonal treatment , immunotherapy At least 14 day since prior concurrent investigational drug No concurrent participation another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
</DOC>